Cargando…

Pre-treatment HIV drug resistance testing cost-effectiveness

Detalles Bibliográficos
Autores principales:	van de Vijver, David AMC, Nichols, Brooke E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251652/ https://www.ncbi.nlm.nih.gov/pubmed/32478315 http://dx.doi.org/10.1016/j.eclinm.2020.100381

Ejemplares similares

Epidemiological impact and cost‐effectiveness of providing long‐acting pre‐exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study
por: van Vliet, Marjolein M, et al.
Publicado: (2019)

Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study
por: Nichols, Brooke E, et al.
Publicado: (2014)

Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058
por: van de Vijver, David A M C, et al.
Publicado: (2019)

Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study
por: Nichols, Brooke E., et al.
Publicado: (2013)

Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women
por: Duarte, Horacio A., et al.
Publicado: (2020)

HIV drug resistance testing – The quest for Point-of-Care
por: Noguera-Julian, Marc
Publicado: (2019)

Point-of-Care Tests for HIV Drug Resistance Monitoring: Advances and Potentials
por: Chua, Rayeil J., et al.
Publicado: (2022)

Quality of life among people living with HIV in England and the Netherlands: a population-based study
por: Popping, Stephanie, et al.
Publicado: (2021)

Targeted HCV core antigen monitoring among HIV-positive men who have sex with men is cost-saving
por: Popping, Stephanie, et al.
Publicado: (2019)

Are We Ready for NGS HIV Drug Resistance Testing? The Second “Winnipeg Consensus” Symposium
por: Ji, Hezhao, et al.
Publicado: (2020)

Feasibility of Four Interventions to Improve Treatment Adherence in Migrants Living with HIV in The Netherlands
por: Been, Sabrina K., et al.
Publicado: (2020)

Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men
por: Popping, Stephanie, et al.
Publicado: (2019)

Letter to the editor: Pre-exposure prophylaxis for HIV in Europe: The need for resistance surveillance
por: van Tienen, Carla, et al.
Publicado: (2017)

Bioinformatic data processing pipelines in support of next‐generation sequencing‐based HIV drug resistance testing: the Winnipeg Consensus
por: Ji, Hezhao, et al.
Publicado: (2018)

Drug costs in context: assessing drug costs in cost-of-illness analyses
por: Mattingly, T Joseph, et al.
Publicado: (2022)

HIV Drug Resistance in Resource-limited Countries: Threat for HIV Elimination
por: Ngo-Giang-Huong, Nicole, et al.
Publicado: (2019)

External Quality Assessment for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Unique Requirements and Challenges
por: Lee, Emma R., et al.
Publicado: (2020)

In vitro tests for drug resistance in Plasmodium falciparum
por: Wernsdorfer, Walther H.
Publicado: (2012)

Dry Panels Supporting External Quality Assessment Programs for Next Generation Sequencing-Based HIV Drug Resistance Testing
por: Noguera-Julian, Marc, et al.
Publicado: (2020)

Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort
por: Bartha, István, et al.
Publicado: (2013)

Characteristics and short- and long-term direct medical costs among adults with timely and delayed presentation for HIV care in the Netherlands
por: Popping, Stephanie, et al.
Publicado: (2023)

The Downstream Impacts of High Drug Costs for PrEP Have Hindered the Promise of HIV Prevention
por: Farrow, Kenyon
Publicado: (2022)

Partner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study
por: Nichols, Brooke E., et al.
Publicado: (2015)

Following the path: Increasing trends of HIV-1 drug resistance in China
por: Gupta, Soham, et al.
Publicado: (2020)

HIV CTL escape: at what cost?
por: Smith, Stephen M
Publicado: (2004)

Cost and Impact of Dried Blood Spot Versus Plasma Separation Card for Scale-up of Viral Load Testing in Resource-limited Settings
por: Nichols, Brooke E, et al.
Publicado: (2020)

The proposed Drug Resistance Index (DRI) is not a good measure of antibiotic effectiveness in relation to drug resistance
por: Vandenbroucke-Grauls, Christina M J E, et al.
Publicado: (2019)

HIV-1 Subtype C, Tenofovir, and the Relationship With Treatment Failure and Drug Resistance
por: Günthard, Huldrych F., et al.
Publicado: (2016)

The Search for Cost-Effective Treatment of Chronic Hepatitis B
por: Smith, Vanessa E., et al.
Publicado: (2008)

Structures of Reverse Transcriptase Pre- and Post-Excision Complexes Shed New Light on HIV-1 AZT Resistance
por: Scott, Walter A.
Publicado: (2011)

Universal Access to HIV Treatment versus Universal ‘Test and Treat’: Transmission, Drug Resistance & Treatment Costs
por: Wagner, Bradley G., et al.
Publicado: (2012)

High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children
por: Boerma, Ragna S, et al.
Publicado: (2016)

Community-based delivery of HIV treatment in Zambia: costs and outcomes
por: Nichols, Brooke E., et al.
Publicado: (2021)

Cost-effectiveness of HIV Prevention Interventions: Estimates from Real-world Implementation Needed
por: Peebles, Kathryn, et al.
Publicado: (2019)

What will it take for an injectable ARV to change the face of the HIV epidemic in high‐prevalence countries? Considerations regarding drug costs and operations
por: Meyer‐Rath, Gesine, et al.
Publicado: (2023)

Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis
por: Rens, Neil E, et al.
Publicado: (2020)

High prevalence of pre-treatment HIV drug resistance in Papua New Guinea: findings from the first nationally representative pre-treatment HIV drug resistance study
por: Gare, Janet, et al.
Publicado: (2022)

The Pursuit of Transparency and Quality Improvement in Cost-Effectiveness Analysis – A Case Study in Disease-Modifying Drugs for the Treatment of Multiple Sclerosis
por: Bell, Christopher F.
Publicado: (2011)

HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report
por: van Kampen, Jeroen J.A., et al.
Publicado: (2022)

Weighing the Risk of Drug Resistance With the Benefits of HIV Preexposure Prophylaxis
por: Grant, Robert M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bep0dis9tkkre8c618c5r3otht